For how we live.
Pooling 19 studies, researchers found all-cause mortality raised about 1.7-fold in people with ADHD, with suicide and injury deaths most elevated — while those on ADHD medication had lower all-cause mortality.
A single-centre randomised trial found the Bergen 4-day treatment cut obsessive-compulsive symptoms far more than an unguided internet CBT programme, with 61% responding at three months versus 25%.
A prespecified analysis of 227,502 veterans who contacted the Veterans Crisis Line found suicide mortality of 0.29% among caring-letter recipients versus 0.27% in historical controls — no measurable difference.
Teva's subcutaneous depot is built to avoid the post-injection sedation that hobbled the first olanzapine shot. It cleared the FDA on 8 October; in the phase 3 SOLARIS trial it beat placebo on symptoms at eight weeks.
A Global Burden of Disease analysis puts substance use disorder prevalence at 0.78% across the Arab League in 2023, about 63% below the global figure — yet women's opioid prevalence topped men's in 19 of 22 countries.
The final FY2027 rule lifts the federal per diem base rate to $912.40 and the electroconvulsive-therapy rate to $688.59 from 1 October, adds a standardised patient-assessment tool, and drops two quality measures.
Ketamine cuts suicidal thinking fast but briefly. A 50-person trial gave low-dose buprenorphine afterward and saw the effect hold — an early, single-centre result in a high-risk group.
A Global Burden of Disease 2023 analysis of 31 countries finds the burden climbing, peaking in early adolescence and heavier in women, with population growth the single biggest driver.
There is no approved drug for methamphetamine use disorder. In 339 patients treated in ordinary clinics, a generic antidepressant cut use by about two days a month more than placebo, with more dropouts from side-effects.
In the industry-funded trial, young responders who kept taking the dopamine D1 blocker relapsed less than those tapered to placebo. The effect was clear in children but not in the small adult group.
Sleeping apart is increasingly common and can genuinely cut disturbance. But the lab evidence is double-edged: sharing a bed measures as slightly worse sleep yet feels better, and may even boost REM.
Rejoyn, the first prescription digital therapeutic cleared for major depression, beat a sham app on a backup analysis. Its pre-specified primary endpoint fell just short of significance.
Knowing you are dreaming and sometimes steering it is real and surprisingly common, and it can be trained. But deliberately inducing it may carry a mental-health cost for some people.
In two randomised trials, a grief-specific psychotherapy roughly doubled response rates against strong comparators. Citalopram alone did not beat placebo — but it did help the depression that often travels with grief.
The largest synthesis of experimental sleep research finds that shorter, broken or lost sleep flattens positive emotion and ramps up anxiety — and trials that fix sleep improve mental health in turn.
Across 154 studies, activities that lower arousal — slow breathing, meditation — reduced anger and aggression. Venting-style activities that raise it, like hitting a bag or going for a run, did not.
At high doses caffeine reliably provokes anxiety and can trigger panic attacks in vulnerable people. The effect is dose-dependent, habitual drinkers differ, and disrupted sleep is part of the story.
Slow breathing does shift the body toward calm, but the popular 4-7-8 count has almost no direct trial evidence, and the breathwork that has been tested in a large study is a different pattern.
Repeating 'I'm a lovable person' left people with low self-esteem feeling worse in controlled experiments. A different technique — writing about your core values — has stronger evidence behind it.
A 40-person Harvard trial aimed accelerated magnetic stimulation using each patient's own connectivity scan. Depression scores fell further than with standard scalp measurement, though the trial was small.
The popular 21-day rule has no basis in the habit-formation research. In the one real-world study, the time to reach automatic behaviour ranged from 18 to 254 days — and plateaued on average near 66.
Two meta-analyses of 104 trials found music lowered both felt stress and physical markers like heart rate. The effect is consistent and moderate — larger for how stressed people feel than for blood pressure.
Task-sharing therapy to lay community workers is the backbone of WHO's plan for closing the treatment gap. A synthesis of 28 studies asks what the model costs the workers themselves.
In the RESPOND randomised trial, guided self-help and remote problem-solving delivered by non-professionals cut anxiety and depression scores well below usual care at follow-up.
Bigger weekly doses of nature track with better wellbeing, structured outdoor programmes ease depression and anxiety in trials, and a single walk can quiet the overthinking that feeds low mood.
Writing about your thoughts and feelings has a real but small average effect across 146 trials; a web-based journaling study eased anxiety in medical patients. Useful, not a cure.
Disordered eating is far more common in adolescents than most parents realise, and weight is a poor guide. A pooled analysis found about 22% of children and teens screen positive, and girls far more than boys.
Nightmare disorder affects about 4% of adults. The treatment with the clearest backing is not a drug but a rehearsal technique that rewrites the dream while you are awake.
Housing is a health exposure. The mortality data on homelessness are among the starkest in medicine — and a large share of the deaths are from causes health care can treat.
Rumination — replaying the same worries on a loop — is a genuine risk factor for depression, and the best trials show it can be trained down, though no single technique clearly beats the rest.
A network meta-analysis of 54 trials put behavioural and cognitive therapies ahead of the drugs on OCD symptoms. But most therapy trials also allowed antidepressants, hinting the two work best together.
A 43-year meta-analysis found loneliness in young adults rising by about half a standard deviation — while its own authors call the word 'epidemic' exaggerated. The pandemic added a small further bump.
The best single randomised trial found morning light beat a sham device over eight weeks, but the effect is most reliable when light is added to an antidepressant rather than used alone.
EndeavorRx is a prescription game the FDA cleared in 2020 for children with ADHD. Its pivotal trial moved a computer attention score, but the FDA says it may not help the behaviour parents notice.
The evidence that recessions and job loss kill is stronger than it looks. Three landmark studies quantify the mortality signal — and where it stops being causal.
A Cochrane network meta-analysis compared eight talking therapies for panic disorder. Cognitive behavioural therapy came out ahead most often — but the effects were small and the evidence graded low throughout.
A gratitude habit gives most people a genuine but small lift in wellbeing — a 2025 meta-analysis of nearly 25,000 people put the average effect at a modest 0.19 — and its unique benefits are probably overstated.
A dormant breach-notification rule became an enforcement tool in 2023, when the FTC fined GoodRx and BetterHelp for sharing users' health data with ad platforms. A 2024 rule change locked apps into its reach.
Companion chatbots eased loneliness as much as talking to a person in one set of studies — and the same research documents emotional dependence and users who are lonelier to begin with.
Pooled trials put the herb roughly on a par with standard antidepressants for mild-to-moderate depression, with fewer dropouts for side effects. The catches are dangerous drug interactions and wildly variable products.
In a 304-veteran trial, prazosin matched placebo on trauma nightmares and sleep quality. Sleep medicine's one recommended treatment for nightmare disorder is a behavioural therapy, not a drug.
The endorphin story is a long-standing guess. When researchers blocked opioid signalling in 63 runners, the euphoria and calm still arrived — pointing to the body's own cannabis-like molecules instead.
The largest network meta-analysis of social anxiety disorder ranked 41 options against each other. Individual CBT came out on top, and it was one of only two treatments to clearly beat a placebo.
In surveys of internally displaced Haitians, 57.2% reported severe PTSD symptoms and 68.3% clinically significant depression. Community violence was the strongest correlate; resilience helped only at the margins.
In a 230-patient randomised trial, self-guided app hypnotherapy produced a 33% pain response versus 48% with an in-person therapist and 22% with education — falling short of non-inferiority.
Two of the largest datasets — 6.5 million UK bank customers and a Swedish national registry — tie heavier gambling to financial and health decline, and gambling disorder to a fifteenfold suicide death rate.
Compulsively scrolling bad news tracks with worse mental and physical health — but the strongest studies show association, not proof, and the scariest prevalence figure shrank by half on replication.
In a 619-patient NEJM trial of treatment-resistant depression after 60, augmenting an antidepressant with aripiprazole improved well-being more than switching to bupropion. The margin was modest.
Large cohorts link higher optimism and a stronger sense of purpose to longer life and lower mortality, in a dose-dependent way. But the studies are observational, and no trial has proved the causal arrow.
The largest network meta-analysis of brain stimulation found several forms of TMS roughly triple the odds of responding, but they sit below ECT and rest on mostly small, uncertain trials.
In the trial that pitted them against each other, aerobic exercise matched sertraline on remission. But both sat only a little above a strikingly strong placebo, which is the part the headlines skip.
US national survey data put lifetime binge eating disorder at 2 percent of men and anorexia at 0.3 percent. Men are underdiagnosed, and the male-specific presentation often hides as gym dedication.
The evidence is real but modest, and stronger for anxiety than for sleep itself. One 120-person trial found a large benefit; pooled analyses across studies find a smaller, more uncertain effect.
Cobenfy, approved in the US in September 2024, cut symptom scores more than placebo in two five-week trials — without the weight gain and movement effects of older drugs, but with cholinergic side effects.
In the largest head-to-head trial, a simpler therapy delivered by junior staff matched full CBT — mean difference 0.1 PHQ-9 points. A Cochrane review finds no difference between the two.
In the largest network meta-analysis, EMDR and trauma-focused CBT were the most effective treatments for adults with PTSD. The evidence is graded moderate-to-low, and the eye movements may not be why it works.
Dopamine is a learning signal that tracks surprise, not a pleasure tank you drain and refill. Stripped of the neuroscience label, the practice is ordinary stimulus control — and that narrower version has some support.
Restrictive English schools cut phone use during the school day but not overall — and teenagers' wellbeing was no better than at schools that allow phones. What tracks with worse mental health is heavy, problematic use.
In the largest trial, combining fluoxetine with talking therapy helped most, and both worked better than placebo. A later network analysis found only fluoxetine, alone or with therapy, clearly beat placebo.
Registry and responder cohorts document persistent PTSD and depression, a symptom peak more than a decade after the attacks, and a burden that compounds with chronic physical illness.
Men die by suicide two to four times as often as women in most countries. The reasons implicate lower help-seeking and masculine norms — and the interventions tested so far have not been shown to reduce it.
A meta-analysis of consumer neurofeedback found no benefit for cognition, mindfulness or physical health and only a small effect on distress — even though the headbands do record real brain activity.
US men die at higher rates than women at almost every age. In younger men the gap is driven by injuries, overdose and suicide; in older men by heart disease — with delayed help-seeking a recurring thread.
In the SKYLARK trial, a 14-day course improved depression scores faster than placebo. The effect was real but modest, and the label carries a driving-impairment warning.
A five-year panel study found sales of mental-disorder medicines rose 144% in a cyclone's landfall year and 173% the next in coastal districts, with no measurable effect further inland.
Resistance training in adults averaging 75 with vascular cognitive impairment, and aerobic exercise in adolescents. Both beat their control, and both controls were active rather than nothing.
An arthritis antibody and a diabetes drug were given to depressed patients in 2026 trials. Both were designed to probe a mechanism rather than prove a treatment, and reading them as results would be a mistake.
A subculture built on ranking faces sits directly on top of a recognised, treatable mental illness. The distress, not the jawline, is the part the evidence says to take seriously.
Two 2026 trials point the same direction: the hardware in depression treatment is mature, and the remaining gains are in precision and in what the treatment costs the patient's memory.
Extreme-leanness culture rebrands restriction as discipline. The evidence is a mental-health story: eating disorders carry among the highest mortality in psychiatry, and under-fuelling harms the body first.
The best evidence frames procrastination as a way of dodging bad feelings about a task, not a scheduling flaw — and following students over a year, more of it tracked with more depression, anxiety and stress.
Among 383 dialysis patients, 83.6% screened for moderate-to-extreme anxiety and 58% for PTSD; a separate study of 250 displaced adolescents found trauma exposure tracking closely with post-traumatic symptoms.
Structured counselling for a spouse delayed a patient's nursing-home admission by an estimated 557 days. Other trials cut carer depression sharply, though the effect on institutionalisation is less consistent.
A Cochrane review of 79 trials and 24,308 patients found the primary-care model helps with depression and anxiety, modestly in the short and medium term and not at all in the very long term.
The word covers everything from sunscreen to self-surgery. The low-risk end has real evidence behind it; the invasive end is where the harm sits, and the whole subculture carries a mental-health cost.
In 415,000 New Jersey births, infants of mothers who screened positive for depression died before age one at more than three times the rate, an association steady across race, income and preterm birth.
A German trial in 1,793 students found a cognitive-behavioural programme reduced gaming and internet-use disorder symptoms only in high-risk adolescents — not across the whole classroom.
Two small pilot studies in 18-to-25-year-olds found morning bright light on its own shifted circadian timing little, while adding a timed schedule and evening blue-blockers advanced it about 35 minutes.
A network meta-analysis of 163 trials found EPA, vitamin D and a St John's wort extract beat placebo by margins so large the researchers treat them as a warning about the evidence, not a green light.
Dronabinol beat placebo on a nightmare-severity scale in 171 adults, but the effect was moderate and the only serious adverse events occurred in the drug group. Long-term safety is untested.
Analysing 4,504 German twins, researchers found the pollution–wellbeing link ran mostly between families, not within twin pairs — pointing to shared circumstances as much as the air itself.
Loneliness and isolation raise mortality risk about as much as well-known risk factors. But trials of interventions to relieve them in older people are mostly low-quality, and the best do more than arrange company.
Two popular stories — alcohol as a cause of low mood, and drinking as self-medication for it — both get less support from recent genetic and within-person data than the confident telling suggests.
A Swiss study tracking people who switched to remote work found no measurable change across 13 health outcomes. A review of pandemic homeworking found the relationship varies so much that no consensus emerged.
Two large re-analyses of the same public datasets found the association is real, negative and very small. A third review found the association is not even consistent between the Global North and South.
A landmark cohort found strained spousal caregivers had a 63% higher death rate over four years. Decades of trials show interventions help — more for a carer's knowledge and mood than for the underlying burden.
Across 34 trials, mindfulness apps produced small effects on stress, anxiety and depression, and none on general distress. A 2026 review confirms they can help without a facilitator — at low certainty.
The MTA trial randomised 579 children and found medication management clearly superior short-term. Its own long-term follow-up found the treatment groups no longer differed by 6 to 8 years.
WHO's ICD-11 lists burn-out, yet places it among reasons people contact health services, not among illnesses. It is defined strictly as a workplace phenomenon, which shapes who should be assessing it and how.
Two NCAA surveys nine weeks apart put the share of Division I men's basketball players receiving abuse tied to betting at 36% and 46%. The gap between them is the most informative part.
Fatal disease burden fell 10% in two decades. Non-fatal burden — the toll of living with illness rather than dying from it — rose 7% over the same period. Mental health diagnoses in young adults nearly doubled.
Twenty-three studies, mostly from the US and China, found mental health risk rising with temperature. Nowhere in the Pacific or Africa was represented.
The agency compressed review of three psychedelic therapies from a year to weeks. A first approval decision is plausible by early 2027.
PMDD is the severe, mostly psychological form of premenstrual illness, affecting about 3.6% of women in one study. For it, SSRIs are the best-evidenced treatment, with side effects that are common and dose-related.
A cross-sectional study of 96 war amputees, 53 caregivers and 95 community controls found sharply elevated disability and psychiatric symptoms, and argued for combined physical and mental-health rehabilitation.
In the first humanitarian trial of its kind, 400 refugees and hosts were randomised. AUDIT scores fell 4.6 points more with screening and brief intervention than with usual care at six months.
Simtriyo works on a different neurotransmitter pathway than existing stimulants. But its own manufacturer classifies it as a CNS stimulant, so a scheduling review stands before pharmacy shelves.
A low-probability alert still sends most recipients to a doctor. Researchers are now naming the flip side of continuous self-monitoring — a device-driven health anxiety they call technohypochondria.
Stress peaked during the fasting month and fell afterwards, but depression and anxiety stayed flat. The consistent finding across every phase was that sleep quality tracked mental health.
The UK and Rwanda reported the highest anxiety, depression, and vasomotor symptom scores; Nepal, Sri Lanka, Malaysia, and Singapore reported the lowest. Burnout emerged as the symptom most connected to everything else.
A quasi-experimental analysis of 23 hospitals finds about 95 additional self-harm and suicide-related emergency visits a month after the law changed, alongside fewer psychiatric admissions.
A Danish registry study of 136,842 women found elevated antidepressant and anxiolytic prescribing in the decade preceding diagnosis, with psychiatric hospital contacts rising about five years before.
A month-long trial that blocked mobile internet improved mental health and attention, and a one-week social-media break lifted wellbeing. The wider literature is thinner.
Pooled trials find forest therapy lowers stress, anxiety, and blood pressure short-term. But heterogeneity is high and reviewers grade the certainty as low to very low.
A cross-sectional analysis of NICE evaluations found 78 supporting studies behind 30 technologies — and consistent holes in comparators, cost of delivery and adverse-event reporting.
Using genetic variants as instruments, researchers found exercise and wellbeing lowered risk of PCOS, endometriosis and menstrual disorders, while screen time and mood swings raised it.
The first federal survey to ask about psilocybin specifically finds 2.8% past-year use, concentrated among young, white, college-educated men. People with recent depression had 37% higher odds.
The largest syntheses find apps beat doing nothing on depression and anxiety by about a third of a standard deviation — but the edge shrinks against real treatment, and one umbrella review found no convincing proof.
A survey of 243 people reporting persistent difficulty after a psychedelic trip found that how they responded in the moment, avoiding versus accepting, predicted whether trauma symptoms followed.
A 2025 meta-analysis found cold-water immersion cut stress 12 hours later, but not immediately — and its effect on immunity and mood did not hold up.
A meta-regression of 169 trials coded 34 therapeutic ingredients. The most common — psychoeducation, relaxation, mindfulness — were not the ones that best predicted getting better.
Compared with a diabetes drug from another class, GLP-1 agonists were followed by fewer new diagnoses of alcohol, opioid, nicotine and other substance use disorders.
A Utah case-crossover analysis found heat stress and pollution interacting synergistically in the warm season. A Louisiana crisis-hotline study traced hot nights to sleep disruption and unmet basic needs.
The NCAA's fifth GOALS study surveyed 20,887 athletes. Sleep is up across almost every sport. Comfort talking to coaches about mental health has barely moved in a decade.
Mindfulness, yoga, exercise and positive psychology landed within a narrow band of each other. Only combining exercise with a psychological approach pulled clear, and nature-based programmes did not beat controls.
A population study covering all 15 million residents of Ontario found the rate of new ADHD medication prescriptions accelerated sharply after 2019 — and shifted decisively toward adults.
A national registry analysis found the highest burden among 20-to-29-year-olds and a notable rise among girls aged 10 to 19, with rates concentrated in the Sierra region.
Across 40 trials, self-guided apps moved panic severity modestly and barely touched fear-related cognitions. Clinician-guided versions moved both — which complicates the scalability pitch.
Across 2.48 million survey responses in 159 countries, the share of people with no one to turn to rose 13.4% between 2009 and 2024 — all of it after 2019.